CGM Uptake for T2D in Primary Care and Endocrinology: Rates, Correlates, Considerations

Continuous glucose monitoring (CGM), long an established standard of care in management of type 1 diabetes, is increasingly being demonstrated as a valuable tool in helping patients wtih type 2 diabetes (T2D) monitor glycemic patterns whether or not they are treated with an intensive insulin regimen that requires multiple daily injections.

Recent studies have found that patients with T2D on basal insulin alone as well as on non-insulin treatments benefit from CGM with positive outcomes including reductions in HbA1c and increases in time in glycemic range. A number of investigations have explored CGM prescribing in primary care, the setting for the majority of T2D care.

Researchers from Vanderbilt University Medical Center (VUMC) recently reported results from the first study to examine trends in CGM uptake in patients with T2D in a real-world settings, finding rapid increases driven by CGM prescribing in primary care. Following are highlights from the single-center retrospective cohort study.